country

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Non-small cell lung cancer

Definition:

Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer and represents a heterogeneous group of cancers, consisting mainly of squamous cell (SCC), adeno (AC) and large-cell carcinoma. Molecular mechanisms altered in NSCLC include activation of oncogenes, such as K-RAS, EGFR and EML4-ALK, and inactivation of tumorsuppressor genes, such as p53, p16INK4a, RAR-beta, and RASSF1. Point mutations within the K-RAS gene inactivate GTPase activity and the p21-RAS protein continuously transmits growth signals to the nucleus. Mutations or overexpression of EGFR leads to a proliferative advantage. EML4-ALK fusion leads to constitutive ALK activation, which causes cell proliferation, invasion, and inhibition of apoptosis. Inactivating mutation of p53 can lead to more rapid proliferation and reduced apoptosis. The protein encoded by the p16INK4a inhibits formation of CDK-cyclin-D complexes by competitive binding of CDK4 and CDK6. Loss of p16INK4a expression is a common feature of NSCLC. RAR-beta is a nuclear receptor that bears vitamin-A-dependent transcriptional activity. RASSF1A is able to form heterodimers with Nore-1, an RAS effector. Therefore loss of RASSF1A might shift the balance of RAS activity towards a growth-promoting effect.

References:

[1]. Anna D Panani, et al. Cytogenetic and molecular aspects of lung cancer. Cancer Lett. 2006 Jul 28;239(1):1-9. [Content Brief]

[2]. D D Eason, et al. Interferon regulatory factor 1 tryptophan 11 to arginine point mutation abolishes DNA binding. Biochim Biophys Acta. 1999 Jul 7;1446(1-2):140-4. [Content Brief]

[3]. D G Burbee, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 2001 May 2;93(9):691-9. [Content Brief]

[4]. G Sozzi, et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell. 1996 Apr 5;85(1):17-26. [Content Brief]

[5]. Geun Dong Lee, et al. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values. J Thorac Oncol. 2017 Aug;12(8):1233-1246. [Content Brief]

[6]. Issan Yee San Tam, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res. 2006 Mar 1;12(5):1647-53. [Content Brief]

[7]. J Chad Brenner, et al. Translocations in epithelial cancers. Biochim Biophys Acta. 2009 Dec;1796(2):201-15. [Content Brief]

[8]. Jong Woo Lee, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005 Feb 17;24(8):1477-80. [Content Brief]

[9]. Jun Yokota, et al. Genetic alterations responsible for metastatic phenotypes of lung cancer cells. Clin Exp Metastasis. 2003;20(3):189-93. [Content Brief]

[10]. Kengo Takeuchi, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012 Feb 12;18(3):378-81. [Content Brief]

[11]. Manabu Soda, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007 Aug 2;448(7153):561-6. [Content Brief]

[12]. Montserrat Sanchez-Cespedes, et al. Dissecting the genetic alterations involved in lung carcinogenesis. Lung Cancer. 2003 May;40(2):111-21. [Content Brief]

[13]. N Hayashi, et al. Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun. 1994 Aug 15;202(3):1426-30. [Content Brief]

[14]. Qinghua Feng, et al. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):645-54. [Content Brief]

[15]. Raghav Sundar, et al. Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Front Med (Lausanne). 2017 Apr 10;4:39. [Content Brief]

[16]. Ralph Meuwissen, et al. Mouse models for human lung cancer. Genes Dev. 2005 Mar 15;19(6):643-64. [Content Brief]

[17]. S S Wang, et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science. 1998 Oct 9;282(5387):284-7. [Content Brief]

[18]. Shinichi Toyooka, et al. Molecular oncology of lung cancer. Gen Thorac Cardiovasc Surg. 2011 Aug;59(8):527-37. [Content Brief]

[19]. T Takahashi, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989 Oct 27;246(4929):491-4. [Content Brief]

[20]. Thomas J Lynch, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. [Content Brief]

[21]. Vladimira Koudelakova, et al. Non-small cell lung cancer--genetic predictors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Jun;157(2):125-36. [Content Brief]

[22]. Yasuhiro Mitsuuchi, et al. Cytogenetics and molecular genetics of lung cancer. Am J Med Genet. 2002 Oct 30;115(3):183-8. [Content Brief]

Biomedical Dictionary

The Biomedical Dictionary is a comprehensive and professional collection of biological academic terms and subject datas. All explanations are supported by authoritative books or high impact factor literatures, and you can acquire accurate explanations of the biomedical terms you want to know.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z #